This presentation discusses need of cooperative interaction between academia and industry in medical research

1. PATKI 1

2. Industry –Academia
Collaboration
For
Research
PATKI 2
MEDINSPIRE

3. Industry –Academia
Partnership
PATKI 3
MEDINSPIRE
ESSENTIAL ?
COSMETIC !
NICE TO HAVE…..

4. Why it is essential ?
• Best hope for Novel therapeutics
• Shared collaborations is successful.
• Historical evidence ?
• Corticosteroids in COPD
• Nobel prize- Philips Hench-Mayo
Taden Reichstein-Basal Univ, Lew Sarrett-Merck
• SM-Walksman-Rutger Univ. George Merck- 1952
PATKI 4

5. Why Nice to have ?
• Unmet patient needs
• Contribution to public health –
• Any one or both
• Effective partnership !
• Recognition
PATKI 5

6. Why it can be Cosmetic ?
• Industry-
• Self sufficient
• Requirements –different
• Contract is difficult
• Secrecy anxiety
• Intellectual property
• TIME CONSTRAINTS
• Academia
• Apathy to applied
• Comfort zone- T/R
• Restrictive environment
• Academic rules and
regulations
• Lack of incentives
PATKI 6

7. Constraints
Academia
• Wary of industry
• Drug discovery- serendipity
• Drugability-
• Feeding and appetite ?
• Quality control job ?
• Tests for products ?
• Useful for academic
excellence ?
• Appreciation Vs
Apprehension
Industry
• Wary of academia
• At the cost of basic
research?
• Academic freedom !
• Is the target drugable ?
The target validated ?
• Contract model. Cost ?
• 95% failure rate
PATKI 7

8. GOALS
Academia
• Knowledge,
understanding of
mechanisms
• N M E
• Grant and support
• PUBLICATIONS
•
Industry
• Informatics
• New avenues, profits
• NEW Product
• New strategies
• Patenting
PATKI 8
NEW BIOLOGICAL,CLINICAL TRIALS
Translating complementarity

9. PATKI 9
Drug discovery is not for the FAINT hearted
Clinician

10. PATKI 10
SLOW , PATIENCE

11. PATKI 11
COLLABORATION POSSIBILITY

12. PATKI 12
CDD Vault is a lifesaver. We really needed a
way to capture the data we were creating and be
able share and analyze it — before we were
capturing data on spreadsheets.“
MALCOLM KENDALL President & CEO,
Indel Therapeutics, Inc.

13. PATKI 13
Win Win situation

14. Public & drug .
And Collaboration
• Drug as ENTITLEMENT
• Drug as High tech product
• Late surprises- Torcetrapib, HDL KING
• 15 Years of drug development
• CVS
• Public liability
PATKI 14
BALANCING

15. Situation also demands
collaboration
60%0f biomedical research and
development is now privately
funded and some academics have
equity ties !
PATKI 15

16. • Derivative medications
• Molecular modifications
• Follow up drugs
• Esomeprazole Omeprazole
PATKI 16

17. COLLABORATION,,,,,,,,,,,
• Unstated expectations- source of
conflict
• Dialogue
• State requirements clearly
• I need X , Now Y, Z
• Honesty in collaborators
PATKI 17

18. Requirements
• Academia-Money- support, payments,
staff.Resources utilization- access to
machinery, methods, materials.
• Data mining.
• Industry- Hits to leads, New
biologicals/ antibodies
• Safe and effective, Holy grain of
computational approach.
PATKI 18

19. PATKI 19

20. PATKI 20
Intricacies

21. Step By Step
• Academic mission- Interaction with
industry and healthcare.
• Medical needs !-Why particular entity is
needed, which category of patients.
• Examples
• Potential drug- Preclinical care, Data-
solubility, permeability, DRS.
• Teacher exemption law- Scientist owning
discovery. Bayh-Dole act.
PATKI 21

22. FURTHER STEPS IN
COLLABORATION
• Time frame (urgency and accuracy)
• Company decision maker
• Legal aspects, signing mutual goals
• Faculty sabbatical in industry
• Chair professor
• Visiting faculty
• Students internship
PATKI 22

23. More steps
• Setting up teams with clarity
• PROJECT MANAGER and his spread
sheet
• Discovery-Potential targets notification
• Bioinformatics and functional genome –
clarity
• Disease model ,Monitoring the progress
• Clinicals PATKI 23

24. Recent success stories
• Prof Cohen. Univ.Dundee.
• Cancer chemo
• First systematic assay to analyse
Kinase inhibition selectivity
• New molecules- kinase inhibitors
• Prof. Dowes-Signal transduction
therapy
• Kinase modulators, phosphatase
modulators.
PATKI 24

25. Theory ?Our Experience
• HD03ES- Hep B
• Random screening of plants,Cyperus rotundus and
scariosus.
• University of Madras –Dr Thyagarajan ,
Dr. Elachezhiyan, Cell line studies, Supernatant
assay, Duck model assay. JSS Mysore. Clinicals –
MAMC, MMC.
• IM133N. Immunomodulation in Cancer .
• NCB 03- Ulcerative colitis
PATKI 25

26. ACADEMIA
Regain, Reignite
Biomedical innovation
PATKI 26

27. JEWISH WEDDING DANCE
PATKI 27

28. Funding
agencies
PATKI 28

29. Funded centers
 Academic drug discovery
consortium
 Medical research council
technology
 Cancer research technology
 CD3- Centre for drug discovery
design
PATKI
29

30. Industrial academic wish
 Can we find a drug that will have
desired effect against targets
 Does modulation of target protein
affect the course of the disease
 Does this project make sense
economically ?
 Exiting gracefully if goals diverge!
PATKI
30

31. Most effective drugs today
PATKI 31
Advances
in basic
biology
Technolog
y
Academia
Pharma-
ProductBuild
on expertiseEarly drug
discovery

32. Chasing innovation
• Academia are well suited. Early work,
• Target discovery
• Target validation
• AI
• Phenotype screening
• Organ on a chip- Human cell
microchips.
PATKI 32

33. Indian scenario
• National policy –Science and
technology.
• Innovation strategies
• NIPERS, AIIMS, PGI. KEM. KGMC, Etc
• Collaboration reports- 120 different
entities
• Global innovation index-
PATKI 33

34. PATKI 34

35. Thank you
PATKI 35